🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. Dendritic cell immunotherapy

    NORTHWEST BIOTHERAPEUTICS INC

    Prostate Cancer

    phase 3 small molecule terminated

    1 trial

  2. Dendritic cell immunotherapy

    NORTHWEST BIOTHERAPEUTICS INC

    Glioblastoma Multiforme

    phase 3 small molecule active

    1 trial

  3. Denifanstat

    Sagimet Biosciences

    MASH

    phase 3 small molecule terminated

    1 trial

  4. Depigoid Grass-Mix (1000 DPP/ml), Conjunctival Provocation Test Grass-Mix LETI 30 HEP/ml, The placebo to be used in the clinical trial is the solvent used in the investigational medicinal products’ (IMPs) formulation. The resulting product is a suspension., Depigoid FORTE Grass-Mix (3000 DPP/ml)

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis with or without controlled asthma

    phase 3 small molecule active

    1 trial

  5. Depot naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Addiction

    phase 3 small molecule completed

    1 trial

  6. Deramiocel (CAP-1002)

    CAPRICOR THERAPEUTICS, INC.

    Muscular Dystrophies

    phase 3 mab active

    1 trial

  7. Descovy or Truvada

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 small molecule completed

    1 trial

  8. Dexa 8 mg inject JENAPHARM Injektionslösung, VELCADE 3.5 mg powder for solution for injection, Dexamethason 8 mg GALEN® Tabletten, Dexamethasone Tablets BP 2.0mg, Dexamethasone 2mg Tablets, Dexa-ratiopharm® 8 mg Injektionslösung, DARZALEX 20 mg/mL concentrate for solution for infusion, Dexamethason 8 mg JENAPHARM®

    GlaxoSmithKline

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  9. Dexamethason CF 20 mg/ml, injectievloeistof, Imnovid 4 mg hard capsules, ELOTUZUMAB, VELCADE 3.5 mg powder for solution for injection, IXAZOMIB , Dexamethason 4 mg JENAPHARM®, Kyprolis 30 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Revlimid 15 mg hard capsules, IXAZOMIB, idecabtagene vicleucel, DARZALEX 20 mg/mL concentrate for solution for infusion, Revlimid 10 mg hard capsules, IXAZOMIB, Revlimid 5 mg hard capsules, Revlimid 25 m

    Celgene Europe Limited

    Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.

    phase 3 small molecule active

    1 trial

  10. Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Lenalidomide Accord 15 mg hard capsules, CARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion, Lenalidomide Mylan 5 mg hard capsules, Lenalidomide Mylan 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Mylan 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, FLUDARABINE , Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 10 mg hard capsules

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  11. Dexamethasone sodium phosphate for encapsulation into autoerythrocytes

    Quince Therapeutics

    Ataxia Telangiectasia (A-T)

    phase 3 small molecule active

    1 trial

  12. Dexmedetomidine 100 micrograms/ml concentrate for solution for infusion, Midazolam Lek 1 mg/ml raztopina za injiciranje/infundiranje

    Tour Hekla

    Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care:

    phase 3 small molecule active

    1 trial

  13. Dextrose / glucose 5% solution in water, Setrusumab

    Lacuna Pharma Pty Ltd

    Osteogenesis imperfecta (OI)

    phase 3 small molecule active

    1 trial

  14. Diacomit 250 mg hard capsules, Matched Placebo will consist in caspules similar to the 250 and 500 mg capsules of stiripentol but with no active ingredient, Diacomit 500 mg hard capsules

    Biocodex

    Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)

    phase 3 small molecule active

    1 trial

  15. Dienogest

    Hospital Authority, Hong Kong

    Endometriosis

    phase 3 small molecule active

    1 trial

  16. Diflucan 200mg Hard Capsules, PLACEBO to Posaconazol hexal, Posaconazol HEXAL 100 mg, NOXAFIL® (posaconazole) Injection, Placebo to bactrim, diflucan 200 mg - microcrystalline cellulose capsules, DIFLUCAN INJECTION, REZZAYO 200 mg powder for concentrate for solution for infusion, Saline solution, REZZAYO 200 mg powder for concentrate for solution for infusion, Bactrim Tablets, NOXAFIL® (posaconazole) Delayed-Release Tablets

    Mundipharma Pty Limited

    Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Marrow Transplantation (BMT)

    phase 3 small molecule active

    1 trial

  17. Directly administered antiretroviral therapy (DAART)

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 other completed

    2 trials

  18. Discontinuation antipsychotic treatment

    Lxo Ireland Designated Activity Company

    Psychosis Nos/Other

    phase 3 small molecule active

    1 trial

  19. Divalproex Sodium

    BRIGHT MINDS BIOSCIENCES INC.

    Attention Deficit and Disruptive Behavior Disorders

    phase 3 small molecule completed

    1 trial

  20. Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  21. Docetaxel+lobaplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma

    phase 3 small molecule active

    1 trial

  22. Dolutegravir/abacavir/lamivudine FDC

    ViiV Healthcare B.V.

    Infection, Human Immunodeficiency Virus

    phase 3 small molecule completed

    1 trial

  23. Domvanalimab

    Arcus Biosciences

    Advanced Upper Gastrointestinal Tract Adenocarcinoma

    phase 3 small molecule active

    1 trial

  24. Donidalorsen

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema (HAE)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources